WASHINGTON — Although the Treasury Department is not likely to call for applications and outline the eligibility criteria until mid-May for the so-called qualifying therapeutic discovery tax credits, biotechs need to start preparing now by identifying potential eligible costs and projects, because the limited funds are likely to go fast, said Ruth Holzman, a partner in the tax department with the Los Angeles law firm Reed Smith LLP. (BioWorld Today) Read More
